Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RHEA-1 AZD9793 in Advanced GPC3-positive Solid Tumors
CTR20254602Phase 2Active
- Sponsor
- AstraZeneca
- Start
- Feb 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of AZD9793 in hepatocellular carcinoma (HCC), sponsored by AstraZeneca. Started Feb 2026; status: active.
02
Drugs
AZD9793
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20254602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254602.